HALOのPER（株価収益率）は？

Halozyme Therapeutics Inc（HALO）は現在PER 20.15倍で取引されています。

HALOのROE（自己資本利益率）は？

Halozyme Therapeutics IncのROEは158.83%です。

HALOの配当利回りは？

Halozyme Therapeutics Incの配当利回りは0.00%です。

HALOの品質スコア（Quality Score）は？

当社のAIはHALOの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

HALOは今が買い時ですか？

当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

HALOはどのセクターに属しますか？

Halozyme Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

HALO (NASDAQ) 株価分析 | HALOZYME THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

HALO AI Analysis Summary

Our AI summary for HALO: Halozyme Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 20.15, ROE of 158.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

HALO

Halozyme Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 82.54

-0.76 (-0.91%) Day Change

Watchlist Portfolio Compare Chart

20.15

P/E

9.76

D/E

158.8%

ROE

13.1%

ROA

0.00%

Div Yield

0.72

PEG

HALOZYME THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 82.54 Price -0.76 (-0.91%) Day Change	NEWS SCORE: 89

HALO, ファンダメンタルスコアはok ( ファンダメンタル = 69) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...

Deepscope 分析

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	750
Magic Formula Rank by ROE	750
Magic Formula Rank by ROIC	827
Price	82.54
PBV / Sector	44.99 / 5.20
Earning Per Share	2.91

PE / Sector	20.15 / 19.97
PEG or PE/Growth / Sector	0.72 / 1.22
Average 1M Daily Value	136.15 M GREAT
Average 1W Daily Value	141.76 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	23.13 / 98.71 GREAT
NPM Average (%) / Sector	30.83 / -1,721.76 GREAT
NPM Change Average (%) / Sector	-1.62 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	13.05 / 27.02
ROA Average (%) / Sector	14.87 / -368.17
ROA Change Average (%) / Sector	10.70 / 5,404.12 GOOD
ROE (%) / Sector	158.83 / 3.47 GREAT
ROE Average (%) / Sector	277.02 / 6.51 GREAT
ROE Change Average (%) / Sector	118.72 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:56
Symbol	HALO
Name	HALOZYME THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	118.61 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	9,880.46 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12390 El Camino Real, San Diego, CA, United States, 92130

Phone: 858 794 8889

Website: https://halozyme.com

Employees: 423

Sector: Healthcare >> Biotechnology

Description: Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.